Frequency of Hyperinsulinemia and Its Relationship with Adiposity and Body Composition in Adolescents and Young Adults Aged 16-25 in Mumbai - Scorecard - MDSpire
Clinical Scorecard: Frequency of Hyperinsulinemia and Its Relationship with Adiposity and Body Composition in Adolescents and Young Adults Aged 16-25 in Mumbai
At a Glance
Category
Detail
Condition
Hyperinsulinemia and Insulin Resistance
Key Mechanisms
Elevated plasma insulin levels and resistance to insulin-mediated glucose uptake.
Target Population
Adolescents and young adults aged 16-25 in Mumbai, India.
Care Setting
Community-based study in academic institutions.
Key Highlights
Increased prevalence of hyperinsulinemia and insulin resistance among youth.
Association between hyperinsulinemia, obesity, and metabolic abnormalities.
Normal-weight individuals can also exhibit hyperinsulinemia and insulin resistance.
Visceral adiposity plays a critical role in metabolic disturbances.
Need for comprehensive assessment of body composition for early detection.
Guideline-Based Recommendations
Diagnosis
Utilize plasma insulin levels to identify hyperinsulinemia.
Assess insulin resistance through appropriate metabolic tests.
Management
Implement lifestyle interventions focusing on diet and physical activity.
Consider monitoring dietary patterns and physical activity levels.
Monitoring & Follow-up
Regular screening for insulin resistance and hyperinsulinemia in at-risk populations.
Track changes in body composition and metabolic markers.
Risks
Increased risk of developing Type 2 Diabetes and metabolic disorders.
Potential for early progression to diabetes-associated complications.
Patient & Prescribing Data
Adolescents and young adults aged 16-25, particularly in urban settings.
Focus on dietary modifications and increased physical activity to mitigate risks.
Clinical Best Practices
Conduct comprehensive assessments of body fat and composition.
Identify and address hyperinsulinemia and insulin resistance early.
Educate patients on the importance of lifestyle changes.
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
